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 ABSTRACT 
Background: 
            Carcinoma stomach is one of the leading causes of cancer related deaths. The potentially 
curative treatment for gastric adenocarcinoma is a complete margin negative (R0) resection. 
Hence, surgery forms the mainstay of treatment of carcinoma stomach. The commonest pattern 
of gastric cancer relapse is peritoneal metastasis which is the foremost cause of death even after 
curative resection is done. Studies have shown that despite radiological findings ruled out 
metastasis, staging laparoscopy contributes substantially in upstaging the disease. 
Also positive peritoneal wash cytology during laparoscopy or laparotomy & proceed indicates 
peritoneal micromets and patients with positive peritoneal wash cytology has been regarded as 
stage IV disease and should be treated with palliative intent. 
Objectives: 
1. To study the Age & Sex incidence of CA Stomach 
2. To study the presenting complaints and mode of presentation of CA stomach 
3. To categorize the anatomical site of tumor 
4. To classify the patients into curative or palliative group 
5. To study the significance of peritoneal lavage cytology during laparoscopy/ laparotomy 
procedure 
Methods: 
The study was conducted on 22 patients diagnosed with adenocarcinoma of the stomach who 
were admitted in Government Stanley Medical College between June 2015 to September 2016. 
Patients admitted with gastric malignancy who satisfied the inclusion and exclusion criteria were 
included in the study. Upper GI scopy and CECT Abdomen were done as a routine to confirm the 
disease and to rule out metastasis respectively. Patients without obvious metastasis in CECT 
Abdomen were subjected to either staging laparoscopy or laparotomy and proceed. 
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During diagnostic laparoscopy, patients with obvious peritoneal and liver mets were noted and 
analyzed. These patients were excluded from taking peritoneal wash cytology. 
Remaining patients with no evidence of mets (during CECT and Laparoscopy) were subjected to 
peritoneal wash cytology and their results were noted and analysed. 
Results: 
Out of 22 patients studied, 4 were women (18%) and remaining 18 were men (82%). Highest 
number of patients, 11 cases (50%) found to be in the age group of 40 to 60 years, 5 cases (22%) 
found to be in the age group of <40 years and 6 cases (28%) were in the age group of >60 years. 
Out of 11 patients with Metastatic CA, 9 patients were greater 50 years. Out of 10 patients with 
Locally Advanced CA, 7 patients were less than 50 years. 
Most common presenting complaints are Abdomen Pain (63%), Vomiting (63%) and LOA & 
LOW (77%). 
Out of 22 patients studied, 9 cases are smoker and alcoholic and remaining 13 cases were non 
smoker and non alcoholic. 
During general examination of patients included in my study, 10 cases were found to be anaemic. 
Out of 10 patients who are Anaemic, 7 patients were Metastatic and 3 patients were Locally 
Advanced. 
Out of 22 patients, 9 cases were presented with Gastric outlet obstruction, 7 cases had 
Abdominal pain, 5 cases had epigastric mass for evaluation and only 1 case with UGI Bleed. 
The most common blood group in my study were O +ve and A +ve (7 cases each). 
During Upper GI Scopy, the most common site of growth were located in Antro pylorus of 
stomach (16 cases) percentage being 72%. 
In CECT (Abdomen and pelvis) of study patients, 8 patients were metastatic. The remaining 14 
patients subjected to D - lap/Laparotomy, 2 cases were found to be metastatic (peritoneal mets) 
and 12 cases were subjected to peritoneal wash cytology out of which 1 case (8.33%) was found 
to be positive for peritoneal cytology. 
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Conclusion: 
Peritoneal Wash cytology during Laparoscopy/Laparotomy though many studies have shown to 
upstage the disease process from locally Advanced to Metastatic. 
Moreover, Positive cytology rate 4.4 – 11% reported in literature which reflects the heterogeneity 
of patient cohorts with variable disease severity, Experience of Pathology, Duration of sample 
retrieval to Sample Analysis & Differences in diagnostic criteria. 
In my study, there were only 1 positive cytology patients out of 12 patients (D-Lap negative) 
examined. Positive cytology rate being 8.33%  
Hence institutional based study should be done to establish the significance of Peritoneal Wash 
cytology in CA Stomach. 
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INTRODUCTION 
The fourth most common cancer is Gastric Cancer and it is the second leading cause of cancer 
death worldwide. High occurrence of local and distant recurrence even in patients with resectable 
gastric cancer suggests the notorious behavior of gastric cancer. These indications suggest the 
systemic spread of cancer very early in the disease process. Rate of gastric cancer in India is less 
compared to worldwide incidence. 
In India, gastric cancer seems to be increasing in North east and Southern parts of the country. 
Incidence of gastric cancer is four times higher in South India than North India and the incidence 
in Chennai is 13.1/1,00,000 population. 
There are only two options available for the Management of Gastric cancer i.e., Curative or 
Palliative. 
Complete operative resection remains the only potentially curative modality for gastric 
carcinoma. 
Gastric cancer is more prone for metastasis apart from CECT Abdomen and chest. Laparoscopic 
staging must form a part of workup to assess Peritoneal and Liver mets which helps to avoid 
unnecessary laparotomy for advanced cases.  
Laparoscopic staging may substantially reduce the need for exploratory laparotomy. Also, 
peritoneal washings can be performed during staging laparoscopy to detect intraperitoneal free 
cancer cells thus patients with radiologically resectable gastric cancer whereas with positive 
peritoneal wash cytology is associated with early disease recurrence and poor survival despite Ro 
resections. 
In this study, apart from Study of Age, Sex, Incidence, Mode of presentation and Site of tumor, 
we subject the patients for peritoneal wash cytology taken either during laparoscopy or 
laparotomy & proceed. Hence patients with locally advanced stage are subjected to peritoneal 
wash cytology during surgery and their results are analyzed. 
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OBJECTIVES 
Objectives: 
1. To study the Age & Sex incidence of CA Stomach 
2. To study the presenting complaints and mode of presentation of CA stomach 
3. To categorize the anatomical site of tumor 
4. To classify the patients into curative or palliative group 
5. To study the significance of peritoneal lavage cytology during laparoscopy/ 
laparotomy procedure 
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REVIEW OF LITERATURE 
ANATOMY 
Anatomically stomach is divided into: 
1. Fundus – Part of the stomach lying above a horizontal plane from cardiac notch to greater 
curvature 
2. Body of the stomach – Part lying between the Fundus and Pyloric part of stomach being 
demarcated from the pyloric part of the stomach by a plane drawn from incisura angularis to 
the greater curvature. 
3. Pyloric portion – further subdivided into  
a. pyloric antrum – extends from incisura angularis to another plane drawn from the 
right end of the bulging of greater curvature. 
b. Pyloric canal – narrowed part of distal stomach extending from end of pyloric 
antrum to pyloric orifice. 
4. Lesser curvature – concave border of the stomach and is continuous with right free border 
of esophagus. 
5. Greater curvature of the stomach – this is the convex border of the stomach and starts at 
left border of esophagus where it joins the stomach. 
 
5 
 
 
  
 
Interior of Stomach: 
1. The stomach shows the same four layers as any other part of G.I.T. 
2. Mucous membrane 
3. Sub mucous layer. 
4. Muscularis propria 
5. Serous layer. 
Mucosa: 
1. Thrown into folds called ‘Rugae’. 
2. The epithelial surface is divided into small areas called mamillated areas – studded with 
numerous depressions called gastric pits.[ gastric glands open in these pits] 
3. The mucous membrane has (i) surface epithelium (ii) lamina propria (iii) glands of 
stomach (iv) muscularis mucosa. 
4. Surface epithelium – Is similar from cardiac to pyloric region – tall columnar cells – 
starts abruptly at the junction between oesophagus & stomach. 
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5. Lamina propria – made up of delicate connective tissue and contains glands of the 
stomach and also infiltrated with lymphocytes through out.  
6. Muscularis mucosa – made up of smooth muscle fibres arranged in inner circular and 
outer longitudinal layers.  
Sub Mucosa: 
Loose connective tissue with collagenous, reticular & elastic fibres along with lymph vessels & 
blood vessels. 
Muscularis propria: 
1. Outer longitudinal layer – continuous with the outer longitudinal layer of oesophagus. 
2. Middle circular layer – continuous with the inner layer of oesophagus. 
3. Intl. oblique layer – not a complete layer. In some places it forms loops of muscle fibres 
extending from cardiac orifice around the fundus & body.   
Serous layer:  
Thin layer of loose connecting tissue underlying a layer of simple squamous mesothelium. 
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Glands of Stomach: 
1. Cardiac portion – contains mucus secreting glands only. 
2. Fundic portion – lies between the pyloric gland area and the cardia – mucosa contain parietal 
cells [acid secreting] & chief cells [pepsin secreting] 
3. Pyloric portion – contains mucus secreting cells & gastrin secreting cells.    
Blood Supply: 
1. Rich arterial supply of stomach arises from the celiac trunk and its branches  
2. Blood is mostly supplied by anastomoses formed along the lesser curvature by the right and 
left gastric arteries, and along the greater curvature by the right and left gastro-omental 
(gastroepiploic) arteries.  
3. Short and posterior gastric arteries supplies blood to fundus and upper body. 
4. The veins of the stomach parallel the arteries in position and course 
5. Lt. gastric artery:  Arises from the coeliac axis and divides into an ascending [oesophageal] & 
descending branch. 
6. The descending branch lying between the layers of lesser omentum is closely opposed to  
lesser curvature & sends branches to the stomach.  
7. Rt. Gastric artery:  Arises from common hepatic artery & divides into many branches along 
the lesser curvature. 
8. Anastamoses with the left gastric artery. 
9. Rt. Gastro epiploic artery: Arises from the gastro duodenal artery – anastamoses with Lt. 
gastro epiploic & forms an arcade supplying the greater curvature.   
10. Lt. gastro epiploic artery: Arises from splenic artery. 
11. Short gastric [vasa brevia]: 5 – 7 small branches arising from splenic artery to supply  
fundus. 
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Venous Drainage: 
1. Venous Drainage Veins: Accompany the arteries, drain into the portal, supr. Mesentric & 
splenic vein. 
2. Lt. gastric [coronary] vein: receives branches from oesophagus 
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Lymphatic Drainage of stomach: 
TABLE – Lymphatic Drainage of Stomach  
Zone I (Inferior gastric) Nodes around right gastroepiploic and gastroduodenal arteries to nodes 
around hepatic artery to celiac nodes 
Zone II (splenic) Nodes around left gastroepiploic and short gastric arteries to 
pancreaticosplenic nodes to splenic artery nodes to celiac nodes 
Zone III (superior gastric) Nodes around the left gastric artery to celiac nodes 
Zone IV (hepatic) Nodes around the right gastric artery to celiac nodes 
 
 
  
 
 
 
 
 
 
 
Eight groups of lymph nodes of stomach from a surgicoanatomic standpoint are: 
1. Paracardial nodes 
2. Left gastric nodes at the left gastric artery 
3. Celiac nodes at the celiac artery 
4. Suprapyloric nodes 
5. Infrapyloric nodes 
6. Right gastroepiploic nodes at the pathway of the right gastroepiploic artery. 
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Nerve supply of stomach: 
Sympathetic – Derived from segments T6 to T10 of the spinal cord via the greater 
splanchnic nerves & the coeliac and hepatic plexuses. 
Vasomotor – Motor to the pyloric sphincter but inhibitory to the rest of gastric 
musculature. 
Parasympathetic – Derived from the vagi, through the oesophageal plexus & gastric 
nerves. Motor – increases motility of stomach.  Secreto motor – For secretion of gastric 
juice. 
Antr. Gastric nerve –  mainly the Lt. vagal fibres – pylorus & antr.surface. 
Postr. Gastric nerve – mainly Rt. Vagal fibres – coeliac branches & postr. Surface. 
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PHYSIOLOGY 
Functions of stomach: 
1. Bulk storage of undigested food  
2. Mechanical breakdown of food  
3. Disruption of chemical bonds via acids enzymes (pepsin) 
4. Production of intrinsic factor  
5. Very little absorption of nutrients  
a. Some drugs, however, are absorbed  
6. Enteroendocrine cells 
Gastric Acid Secretion: 
Acid production by the parietal cells in the stomach depends on the generation of carbonic acid; 
subsequent movement of hydrogen ions into the gastric lumen results from primary active 
transport. 
 
1. One inhibitory and three stimulatory signals that alter acid secretion by parietal cells in 
the stomach. 
2. Gastrinand Ach work by increasing [Ca++] and activate Protein Kinases 
3. Histamine works via a H2receptor and by a cAMP mechanism 
4. All 3 work synergistically.  
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The acidity in the gastric lumen converts the protease precursor pepsinogento pepsin; subsequent 
conversions occur quickly as a result of pepsin’s protease activity. 
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EPIDEMIOLOGY OF ADENOCARCINOMA STOMACH 
The fourth most common cancer is Gastric Cancer and it is the second leading cause of cancer 
death worldwide. In India, gastric cancer seems to be increasing in North east and Southern parts 
of the country. Incidence of gastric cancer is four times higher in South India than North India 
and the incidence in Chennai is 13.1/1,00,000 population. Over the past few decades incidence of 
gastric cancer is decreasing in trend. This decrease is more in the intestinal form of gastric cancer 
rather than diffuse variety. 
Gastric cancer is the disease of elderly.  
In younger patients, tumors are  
Diffuse variety, 
Tends to be large and aggressive, 
Poorly differentiated. 
Incidence of gastric cancer is shifting from distal to proximal stomach.  
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ETIOLOGY OF GASTRIC CANCER 
Gastric cancer is more common in patients with pernicious anemia, blood group A, family 
history of gastric cancer. 
 
Diet and drugs – Starchy diet high in pickled, salted or smoked food carries high risk of 
gastric cancer. Dietary nitrates are also a possible cause of gastric cancer. Diets high in 
fresh fruits and vegetables, rich in vitamin C & D decreases the risk of gastric cancer. 
Tobacco use probably increases the risk of stomach cancer. 
Helicobacter pylori – the risk of gastric cancer in patients with chronic H.pylori 
infection is increased threefold. Patient with history of gastric ulcer are more likely to 
develop gastric cancer than patients with duodenal ulcer. This is because these patients 
develop corpus predominant gastritis resulting in hypochlorhydria and predisposing to 
gastric ulcer and gastric cancer. 
Patients infected with virulent cag A, vacA strains have increased chance of getting 
gastric cancer. Infection decreases acid – pepsin secretion. 
15 
 
  
 
Epstein - Barr virus – 10% of adenocarcinoma harbor EBV virus. EBV transcripts are 
present in cancer cells but not in metaplastic cells of precursor epithelium. 
Genetic abnormalities  
a. Hereditary diffuse gastric cancer 
a.i. Inherited form of gastric cancer resulting from a gene mutation for the cell 
adhesion molecule E-cadherin, 
a.ii. 80% lifetime chance of developing gastric cancer 
a.iii. Prophylactic total gastrectomy should be considered 
b. Familial Adenomatous Polyposis 
b.i. 85% of the patients have fundic gland polyps out of which 40% have some 
type of dysplasia and over 50% have sometic apc mutation. 
c. Li – Fraumeni syndrome – Auto fomal dominant disorder caused by mutation in 
tumor suppressor p53 gene. These patients are at risk of gastric cancer.  
d. Hereditary non polyposis colorectal cancer or Lync syndrome – Associated 
with microsatellite instability. Increased risk of gastric and overian cancer. 
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Premalignant conditions of Stomach 
Polyps:  
Benign gastric polyps are classified as neoplastic (adenoma and fundic gland polyps) or 
non-neoplastic (hyperplastic polyp, inflammatory polyp, hamartomatous polyp.  
Fundic gland polyps seen in patients on long term proton pump inhibitor can cause 
dysplasia in patients with FAP. Hyperplastic polyps > 2cm may harbor dysplasia or 
carcinoma insitu.  
Gastric adenomas are premalignant. Patients with FAP have a high prevalence of gastric 
adenomatous polyp. They have 10 times more chance of developing adeno carcinoma 
of the stomach than the general population. 
Gastric polyps more than 1 cm need to be removed to confirm diagnosis and to prevent 
further risk of malignancy. 
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Atrophic Gastritis:  
It is the commonest precursor for gastric cancer especially intestinal subtype.  
In most patients H.pylori is involved in pathogenesis of atrophic gastritis.  
Correa described 3 patterns of chronic atrophic gastritis.  
a) Auto immune (involves the acid secreting proximal stomach) 
b) Hypersecretory (involving in distal stomach) 
c) Environmental (involving multiple random areas at the junction 
of the oxyntic and antral mucosa). 
Intestinal Metaplasia: 
Gastric carcinoma often occurs insites of intestinal metaplasia. 
Complete type of intestinal metaplasia, glands are completely lined with goblet cells 
and intestinal absorptive calls.  
Eradication of H.pylori infection leads to regression of intestinal metaplasia and 
improvement in atropic gastritis. 
Benign gastric ulcer:  
All gastric ulcers are cancer until proven otherwise with adequate biopsy and follow up. 
Carcinomas are occasionally found when biopsied benign ulcers are resected for non 
healing. 
Gastric Remnant cancer:  
Stomach cancer can develop in gastric remnant following distal gastrectomy for PUD.  
Tumors develop >10 years after the initial surgery and arise in the area of chronic 
gastritis, metaplasia and dysplasia. 
Site is more common near stoma. 
This condition is reported following billroth II gastroenterostomy. 
Menetriers disease:  
Giant hypertrophy of gastric mucosal folds carries 5 to 10% risk of adenocarcinoma. 
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CLASSIFICATION SYSTEMS IN ADENO CARCINOMA 
1. JAPANESE CLASSIFICATION FOR EARLY GASTRIC CANCER (EGC): 
a. EGC is gastric cancer continued to mucosa and submucosa irrespective of lymph 
node status. 
b. 10% of the patients with EGC have lymph node metastatis. 
c. 70% of EGC are well differentiated while 30% are poorly differentiated. 
 
  
 
2. CLASSIFICATION BASED ON GROSS MORPHOLOGY: 
a. Polypoidal – Here bulk of tumor mass is intraluminal, not ulcerated. 
b. Fungating – Here tumors are elevated intraluminally but also ulcerated. 
c. Ulcerative – This type of CA Stomach arises most commonly in pyloric antrum 
region towards lesser curvature side. 
d. Colloid – Appear on massive tumor with gelatinous appearance. 
e. Scirrhous – Rare variety, poor prognosis and involve entire stomach (submucosa, 
submucosal muscle coat without protruding into the lumon of the stomach) 
19 
 
3. BORMANN’S CLASSIFICATION FOR ADVANCED GASTRIC CANCER: 
Advanced gastric cancer extends beyond submucous coat and involves muscularis 
propria. Classification is as follows: 
Type I – Protruded 
Type II, III, IV – Depressed type  
 
 
4. LAURENS CLASSIFICATION OF GASTRIC CANCER BASED ON HISTOLOGY: 
Type I (53%): 
Intestinal type,  
Arises insite of intestinal metaplasia 
Forms polypoid tumor or ulcer.  
Associated with Chronic Atrophic Gastritis, severe intestinal metaplasia and 
dysplasia 
Tends to be less aggressive. 
Type II (33%): 
i. Diffuse type,  
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ii. Infiltrates deeply in the stomach wall without producing obvious mass 
lesion.  
iii. Associated in younger patients with proximal tumor  
iv. Poorly differentiated. 
Type III (14%) – Otherwise not specified.  
 
 
5. WHO HISTOLOGICAL TYPING OF GASTRIC CANCER: 
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RELATIVE SITE DISTRIBUTION OF GASTRIC CANCER: 
a. Pyloric region – 47% 
b. Body of Stomach – 23% 
c. Cardia – 21% 
d. Fundus – 2% 
e. Limits Plastica – 7% 
Recently there may be proximal migration of tumor site. So currently 40% distal, 30% middle 
and 30% proximal. 
PROGNOSTIC FACTORS IN CA STOMACH: 
1. Tumor – Depth of invasion 
2. Metastasis – Lymph node or distant 
3. Histological grading and type – well, moderately or poorly. 
SPREAD OF CANCER STOMACH: 
Carcinoma stomach spread in the different ways: 
1. Direct spread – Spread from mucosa to serosa. Involves adjacent part of stomach to 
adjacent structures like colon, pancreas and liver, esophagus, mesocolon and rarely 
duodenum. 
2. Lymphatic spread – Occurs by permeation and embolization 
a. First tier of lymph nodes – perigastric nodes lying within 3cm of primary growth 
(lymph node station 1 to 6) 
b. Next tier of lymph nodes – nodes around main and intermediate arterial trunk 
(lymph node station 7 to 11) 
c. Regional lymph node - lymph node station 12 to 18 
d. Lymphatic spread may occur 
d.i. Left Virchow’s gland in neck via thoracic duct 
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d.ii. Along the lymphatics in falciform ligament leading to formation of 
subcutaneous nodule. 
3. Blood borne spread – Liver, lungs and brain. 
4. Transperitoneal spread – Tumor cells may exfoliate and drop in peritoneal cavity giving 
rise to Krukenberg’s tumor.  
5. Transluminal spread may occur 
6. Transplantation – At the time of surgery cancer cells may dislodge and implant at the 
sites of abdominal incisions. 
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CLINICAL MANIFESTATION: 
Most common symptoms are weight loss and decreased food intake and most common mode of 
presentation is silent. 
EARLY GASTRIC CANCER: 
1. Specific symptoms 
2. Early vague epigastric discomfort 
3. Indigestion 
4. Constant pain, non-radiating and not relieved by food intake. 
ADVANCED GASTRIC CANCER: 
1. Vomiting due to obstruction 
2. Dysphagia 
3. UGI Bleed 
SPECIFIC SYMPTOMS: 
1. Proximal tumor – Dysphagia 
2. Distal tumors – GOO 
3. Diffuse variety – Early satiety 
4. GI Bleed is rare 
PHYSICAL SIGNS: 
1. Weight loss and anemia 
2. Palpable mass 
3. Gastric outlet obstruction 
4. Ascites 
5. Jaundice 
24 
 
SIGNS OF INOPERABILITY: 
1. Left supraclavicular node (Virchow’s node) 
2. Ascites 
3. Fixed mass/posterior fixation 
4. Liver metastases (Hepatomegaly, Jaundice) 
5. Blumer’s shelf deposit (peritoneal metastasis felt as firm shelf on rectal examination) 
6. Irish node 
7. Sister Mary Joseph nodule (Periumblical nodule) 
8. Krukenberg’s tumor (drop metastasis to ovary) 
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PATHOLOGIC STAGING: 
The most widely used staging system is AJCC TNM Staging system. This is based on  
Depth of tumor invasion (T) 
Number of involved nodes (N) 
Presence or absence of metastasis (M) 
Minimum of 15 nodes must be evaluated for accurate staging. 
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Following is the Japanese Gastric Cancer Association definition of Lymph node station number. 
 
R status described by Hermanek describes tumor status post resection and is important for 
determining the completeness of surgery.  
1. R0 – microscopically margin-negative resection, in which no gross or microscopic tumor 
remains in the tumor bed.  
2. R1 - removal of macroscopic disease, but microscopic margins are positive for tumor. 
3. R2 - gross residual disease.  
STAGING WORKUP: 
1. To ascertain prognosis to counsel the patient and family. 
2. To diagonise the extent of disease and determine course of treatment. 
 
 
 
 
27 
 
ORDER OF INVESTIGATIONS IN STAGING WORKUP: 
1. Upper GI endoscopy 
2. Endoscopic Ultrasound 
3. USG/CT Abdomen and Pelvis 
4. X-ray chest 
5. Blood investigations 
6. Barium meal 
7. Laparoscopy and wash cytology 
8. PET Scan 
Upper GI endoscopy: 
1. Flexible endoscopy is the goal standard tool for the analysis of gastric cancer.  
2. It allows  
a. Visualization of tumor 
b. Provides tissue for pathological diagnosis 
c. Serve as treatment for patient with obstruction or bleeding 
3. Pre-requisites for doing endoscopy: 
a. 8 hours fasting 
b. Facilities for resuscitation – needed 
c. Pulsoximeter – must 
d. Sedation - small incremental doses of Diazepam/Midazolam 
28 
 
e. Spasmolytics ( Buscopan) allows visualisation of antrum and negotiation into 
duodenum 
4. The following point should be noted in endoscopic findings: 
a. Size  
b. Location 
c. Morphology 
d. Extent 
e. Biopsy 
f. Other parts of Stomach 
g. Endoscopic USG  
h. Chromo endoscopy 
5. Endoscopic society classification of EGC: 
a. Type 1 – Protruding 
b. Type 2 – Superficial 
b.i. 2 i – elevated 
b.ii. 2 ii – flat 
b.iii. 2 iii – depressed 
c. Type 3 – excavated 
6. BENIGN VS MALIGNANT: 
1. If benign ulceration is diagnosed, endoscopy and biopsies are to be repeated after 
four to eight weeks of medical treatment to confirm ulcer healing and benign 
nature of the lesion. 
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2. Benign and malignant gastric ulcers differentiation at endoscopy can be difficult, 
hence several biopsies need to be taken (preferably six) from all parts of the ulcer. 
100% diagnostic accuracy can be attained if 10 samples are taken.  
BENIGN ULCER Vs MALIGNANT ULCER: 
 
 
Endoscopic Ultrasound (EUS): 
1. EUS is performed using flexible endoscope with 7.5 to 12 MHz ultrasound 
transducer. 
2. The stomach is filled with water to distend the stomach and stomach wall is 
visualized as five alternating hypoechoic and hyperechoic layers. 
3. The mucosa and submucosa represent the first three layers (T1). The fourth layer is 
the subserosa, invasion represents T2 tumor. The serosa is the fifth layer and tumor 
penetration is the T3 tumor.  
4. Local lesion,regional lymph nodes and left hepatic lobe can be assessed. 
5. Bulk of right hepatic lobe and peritoneum is outside the range of the probe which is 
approx 10cm 
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Gastric CA is seen hypoechoic disruption of the layers and depth of penetration can be 
determined in relation to this: 
1. T1 tumours – disruption of first 3 layers 
2. T2 tumours -  4 layers disrupted 
3. T3 tumours – penetrates through the 5th layer 
4. T4 lesion – invades adjacent structures 
5. N stage – malignant nodes are larger in size with hypoechoic or mixed echogenicity 
with round and sharp borders 
6. Limited use in determining M stage 
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Chromo endoscopy: 
1. To target early lesions 
2. To define their margins 
3. Due to indigo carmine dye it is blue color 
 
 
Barium Meal: 
1. Endoscopy and Barium studies are interdependent.  
2. In case, first investigation in a patient with sinister symptoms is negative then the 
other test is indicated  
3. Degree of obstruction 
4. Diagnosing linitis plastica that can be missed at gastroscopy 
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BENIGN Vs MALIGNANT ulcer: 
1. Benign ulcer 
a. Extends beyond the luminal margin 
b. radiating gastric folds 
2. Malignant ulcer 
a. Doesnot extend beyond luminal margin 
a.i. Folds - Parallel/ interrupted/ fused/ nodular 
b. a/w mass 
c. Ulcer with irregular filling defect 
 
CHEST X-RAY: 
 
Multiple metastases would stop further investigations unless there is a need for trials. 
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Computerized Tomography: 
1. CT is the primary method for detection of intra-abdominal metastatic disease 
(detection rate of approximately 85%). 
2. The ability to image peritoneal metastases is only 50%. 
3. Used in locoregional staging but the accuracy of T and N stages as determined by CT 
is less accurate than EUS. 
4. Detects the following: 
i. Spread beyond the mucosa 
ii. Presence of local tumour invasion  
iii. Regional lymph node metastasis 
iv. Metastasis 
v. Egc has no detectable findings on ct 
5. CT finding in Advanced Gastric CA: 
Infiltrative type - focal or diffuse wall thickening, infiltrated wall shows marked 
contrast enhancement 
Mucinous adeno ca – low density masses with stippled or punctate calcification 
Polypoid tumours – soft tissue masses that protrude into gastric lumen 
Ulcerative type – tumour with central cavitation 
6. CT staging of gastric CA: 
STAGE I - Intraluminal mass only 
STAGE II - Gastric wall thickening > 1 cm 
STAGE III – Gastric wall thickeneing with direct invasion of adjacent structures and 
or local adenopathy 
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STAGE IV - Distant metastasis present 
7. Helical CT abdomen: 
a. Staging and assessment of operability 
b. Extent of mural involvement 
c. Extra gastric extension 
d. Involvement of retrogastric organs 
e. Detection of lymphnodes 
8. Limitations of CT: 
a. In evaluating early gastric cancers 
b. In detecting small ( < 5 mm ) mets in liver and peritoneal surface 
c. Accuracy for LN –  25 – 36% 
PET: 
1. PET is not a primary staging modality for gastric cancer. 
2. Principle of PET Scanning is based on tumor cells preferentially accumulate positron 
emitting 18 – F fluorodeoxy glucose. 
3. Used for evaluating distant metastasis in gastric cancer and also in loco regional 
staging. 
4. Sensitivity - 60% 
5. Specificity - 100% 
6. Possible role: 
a. Staging 
b. Assess response to treatment(NEO-ADJUVANT CHEMO) 
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Staging Laparoscopy and Peritoneal Wash cytology: 
 
For patients with locally advanced gastric cancer and those who received neo adjuvant 
chemotheraphy, Staging Laparoscopy is a safe and effective tool,. The most frequent metastasis 
and recurrence in patients with gastric cancer is peritoneal carcinomatosis. 
Disseminated lesions originate from free cancer cells shred from cancer invaded mucosa. Several 
Japanese Institutions performed Peritoneal Wash cytology to detect these cells. Robustic value of 
positive cytology was also confirmed recently in the West. 
 
Why Staging Laparoscopy should be done? 
Conventional Imaging techniques often understage the extent of intra abdominal spread of 
advanced gastric cancer which results in high rate of unnecessary exploratory laparotomy. 
Clinical staging may be improved by laparoscopy since this may identify the abdominal 
tumor deposits on peritoneal surfaces which are not detectable by contrast CT. Also 
peritoneal wash cytology can be taken during laparoscopy, which found positive can be 
considered as Gastric Malignancy. 
 
Advantages of Staging laparoscopy: 
1. Staging patients for preoperative treatments.  
2. Rate of detecting occult metastatic disease 13 – 37% 
3. Disease missed by CT are mostly peritoneal metastases 
4. Eliminate the need for Laparotomy  
5. Laparoscopic USG 
a. Adjacent organ invasion 
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b. Liver metastases 
c. Guided biopsy of doubtful lesion in liver to r/o benign pathology 
6. Peritoneal wash cytology can be taken during laparoscopy which if found positive 
can be treated with palliative intent. 
Laparoscopy showing liver mets: 
 
Laparoscopy showing peritoneal mets: 
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Peritoneal Wash cytology: 
Positive peritoneal cytology (PC) is associated with poor prognosis. In locally advanced gastric 
cancer, patient should undergo staging laparoscopy and PC to select those requiring different 
treatment. 
Peritoneum is the most frequent site of recurrence following R0 resection, possibly due to intra 
peritoneal presence of shed from the serosal surface of primary tumor. Majority of patients with 
intra peritoneal free cancer cells (IPFCC) do not escape postoperative peritoneal recurrence. 
Clinical studies have shown peritoneal cytology findings as an independent prognostic factor in 
gastric cancer. Hence peritoneal cytology should be included as a Staging process in gastric 
cancer as followed by Japanese research society for gastric cancer. 
Peritoneal Washing Procedure: 
Peritoneal wash fluid should be collected either during staging laparoscopy or laparotomy and 
proceed.  
Immediately on opening the abdomen, 200 ml of warm saline was instilled into the serosa 
overlying the tumor. The fluid was then aspirated from the abdominal cavities including the 
pouch of Douglas. After gentle stirring, atleast 50 ml of the fluid was recovered subsequently. 
Fluid was then centrifuged for 15 mins at 1500 rpm. Supernatant fluid should be discarded. 
Sediment was made on two glass slides and stained by Papanicolau’s method. 
All cytological examinations were performed by experienced cytopathologists.  
Cytological findings were classified as  
Positive,  
Negative or  
Hemorrhagic 
Although IFCC are detected in a considerable number of gastric patients, the probability of 
peritoneal recurrence far exceeds the IFCC detected. The use of real time RT – PCR (real time 
quantitative reverse transcriptase – polymerase chain reaction) has been reported to increase the 
sensibility of IFCC detection.  
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METHODOLOGY 
Patients admitted in various surgical units of Stanley Medical College from June 2015 to 
September 2016 constitute the materials of this study. Clearance was obtained from hospital 
ethical committee. 
All patients admitted with diagnosis of carcinoma stomach by endoscopic biopsy and their 
staging and management were included in this study. A total of 22 patients were analysed. 
A detailed history including dietary factors, life style habits and mode of presentation were 
elicited in all patients and thorough clinical examinations were done in them.  
All patients were subjected to basic blood, urine and biochemical evaluation including liver 
function test and USG abdomen, CECT abdomen/pelvis, diagnostic laparoscopy. Peritoneal wash 
cytology was taken for patients with negative macroscopic metastasis. 
Patients were categorized into various stages (by CECT, biopsy, DPL) and treatment plan was 
made according to stages. 
Patients were operated and operative findings were noted, recorded and analyzed. 
Epidemiological factors relevant to age, sex distribution were noted. 
Specimen was sent for HPE, histological type and grading of tumour was analysed. 
INCLUSION CRITERIA: 
1. Patients with histologically proven CA stomach after upper GI endoscopy. 
2. Patients with negative macroscopic metastasis will be subjected to peritoneal wash 
cytology. 
EXCLUSION CRITERIA (for peritoneal wash cytology): 
1. Patients with obvious metastatic disease will be excluded for peritoneal lavage cytology. 
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DIAGNOSTIC WORK UP: 
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PERITONEAL WASHING: 
1. Peritoneal wash cytology was done either during laparoscopy/laparotomy and proceed. 
2. On opening the abdomen, before manipulating the tumor, 200 ml of warm normal saline 
were introduced and manually stirred in the Douglas cavity, para-colic gutters and in the 
right and left subphrenic cavity.  
3. After gentle stirring, atleast 50 ml of the fluid was recovered subsequently from several 
regions of the abdominal cavity.  
4. The fluid was then centrifuged for 15 min at 1500 rpm.  
5. The sediment was smeared onto one or more glass slides and stained using the 
Papanicolau’s method.  
6. All cytological examinations were performed by experienced cytopathologists.  
7. Cytological findings were classified as positive, negative or suspicious.  
8. The following cell characteristics were used to determine the presence of malignant cells:  
1. Presence of aggregate 
2. size 
3. shape 
4. type of cytoplasm 
5. cytoplasmic vacuoli, mainly nuclear abnormalities  
6. nuclear chromatin 
7. nuclearcytoplasmic ratio 
8. mitotic figures 
9. nucleolar prominence 
Staging Laparoscopy is done to look for evidence of peritoneal, liver metastasis (M+) or 
ascites. The T factor is assessed by looking for serosal involvement or involvement of 
adjacent organs; and the N factor is assessed by involvement of adjacent lymph nodes. 
If either D-Lap shows evidence of metastasis or peritoneal cytology is found to be 
positive, patient is treated with Palliative intent. 
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RESULTS 
Table 9: Age Distribution 
Age 
No of 
patients 
<=40 5 
41 to 50 4 
51 to 60 7 
>60 6 
 
Graph 1: Age Distribution 
 
Table 2: Sex Distribution 
Sex 
No of 
Patients 
Male 18 
Female 4 
 
Graph 1: Sex Distribution 
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Table 10: Age vs No of Patients with Metastatic CA 
  
Age  No of Patients with Metastatic CA 
<50 2 
>50 9 
 
Graph 2: Age vs No of Patients with Metastatic CA 
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Table 11: Age vs No of Patients with Locally Advanced CA 
Age  No of Patients with Locally Advanced CA 
<50 7 
>50 3 
 
Graph 3: Age vs No of Patients with Locally Advanced CA 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
46 
 
 
Table 12: Presenting Complaints 
Complaints No of patients 
Abdomen Pain 14 
Early Satiety 7 
Vomiting 14 
UGI Bleed 5 
Dysphagia 1 
LOA & LOW 17 
 
Graph 4: Presenting Complaints 
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Table 13: Dietary Habits 
Diet Habits No of Patients 
Vegetarian Diet 1 
Mixed Diet 21 
 
Graph 5: Dietary Habits 
 
Table 13: Personal Habits 
Personal Habits No of Patients 
Smoking and Alcoholic 9 
Non smoker and Non alcoholic 13 
 
Graph 5: Personal Habits 
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Table 14: Patients with Anaemia 
General Examination No of Patients 
Normal 12 
Anaemic 9 
Anaemic with Jaundice 1 
 
Graph 6: Patients with Anaemia 
 
Out of 22 patients, 10 patients were anaemic. 
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Table 15: Stage of Disease vs Patients with Anaemia 
Diagnosis No of Patients who are Anaemic 
Metastatic 7 
Locally Advanced 3 
  
Graph 7: Stage of Disease vs Patients with Anaemia 
 
Table 16: Stage of Disease vs HB 
Stage of Disease <8 gms 
8 to 11 
gms 
>11 
gms 
Metastatic 5 2 4 
Locally Advanced 2 2 6 
 
Graph 8: Stage of Disease vs HB 
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Table 17 – Clinical Findings 
Local Examination No of Patients 
Epigastric Mass 7 
No Significant finding 9 
Ascites 2 
Visible Gastric Peristalsis 4 
Hepatomegaly 1 
 
Graph 9 – Clinical Findings 
 
 
 
51 
 
 
 
Table 18 – Mode of Presentation 
Clinical Diagnosis 
No of 
Patients 
Epigastric mass for evaluation 5 
Abdomen pain for evaluation 7 
Gastric outlet obstruction 9 
UGI bleed 1 
 
 
Graph 10 – Mode of Presentation 
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Table 19 – Blood group 
Blood Group No of Patients 
A+ 7 
B+ 5 
AB+ 2 
O+ 7 
B- 1 
 
Graph 11 – Blood group 
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Table 20 – Upper GI Scopy 
Site of growth No of patients 
Antro pylorus 16 
Proximal body 1 
Distal Body 4 
Proximal Body & fundus 1 
 
Graph 12 – Upper GI Scopy 
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Table 21 – Histological Grade 
 
Histological Grade No of patients 
Moderately Differentiated 11 
Poorly Differentiated 9 
Well differentiated 2 
 
Graph 13 – Histological Grade 
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Table 22 – Histological Grade Vs Patients with Mets 
Histological Grade No of Patients with Metastatis 
Moderately Differentiated 5 
Poorly Differentiated 6 
Well differentiated 0 
 
Graph 14 – Histological Grade Vs Patients with Mets 
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Table 23 – Presence of Mets in CECT 
Presence of Mets No of Patients 
Peritoneal Mets 1 
Liver Mets 7 
 
Graph 15 – Presence of Mets in CECT 
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Table 24 – D-Lap/Laparotomy and Proceed findings 
 
D-Lap findings No of Patients 
Peritoneal Mets present 2 
Mets not present 12 
 
Graph 16 – D-Lap/Laparotomy and Proceed findings 
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Table 25 - Wash Cytology in D-Lap negative patients 
Wash Cytology in D-Lap negative patients No of Patients 
Positive for Malignancy 1 
Negative for Malignancy 11 
 
Graph 17 - Wash Cytology in D-Lap negative patients 
 
 
Table 26 - Peritoneal Wash cytology by D-Lap/Laparotomy 
Peritoneal Wash cytology by D-Lap/Laparotomy No of Patients 
Laparotomy 10 
D-Lap 3 
 
Graph 18 - Peritoneal Wash cytology by D-Lap/Laparotomy 
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Table 27 – Final Diagnosis 
Final Diagnosis No of patients 
Early 1 
Locally Advanced 10 
 
Graph 19 – Final Diagnosis 
 
Table 27 – Diagnosis of Metastatic CA stomach 
Method 
Number of patients Diagnosed with Metastatic CA 
stomach 
CECT 8 
D-Lap 2 
Wash cytology 1 
 
Graph 19 – Diagnosis of Metastatic CA stomach 
 
60 
 
Table 28 – Surgery 
Surgery No of Patients 
Curative 11 
Palliative 11 
 
Graph 20 – Surgery 
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FIGURES RELATED TO MASTER CHART 
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DISCUSSION 
The main purpose of staging laparoscopy in gastric cancer is to 
1. Avoid unnecessary laparotomy in incurable metastatic patients. 
2. Staging patients planned for pre operative treatments  
 
Most common site of metastasis in patients with incurable metastatic disease is peritoneum. 
Conventional imaging techniques cannot detect peritoneal mets usually, but surgical laparoscopy 
is very accurate in detecting small intra abdominal metastasis. Studies have shown that 13 to 
37% of patients with peritoneal deposits failed to be detected by contrast CT were picked up by 
staging laparoscopy. 
In another study, 21% of the patients were found to have peritoneal metastasis. These patients 
were able to avoid unnecessary laparotomy/curative surgery. 
 Peritoneal dissemination can be early detected by cytological examination of the 
peritoneal wash cytology. Peritoneal wash fluid can predict survival and peritoneal relapse in 
patients with gastric cancer. 
 Usefulness of peritoneal cytology has been a subject of debate in literature. Survival of 
patients with positive cytology is worse as compared to those with negative cytology. In one 
study peritoneal cytology was positive in 11% of population studied (range being 4.4-11%) 
compared to our study, only one positive cytology patient out of 12 patients (D-Lap negative) 
examined, Positive cytology rate being 8.33%. 
 Hence a broad institutional based study should be done to analyze the significance of 
Peritoneal wash cytology during laparoscopy / laparotomy in unseen metastasis. 
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CONCLUSION 
Peritoneal Wash cytology during Laparoscopy/Laparotomy though many studies have shown to 
upstage the disease process from locally Advanced to Metastatic. 
Moreover, Positive cytology rate 4.4 – 11% reported in literature which reflects the heterogeneity 
of patient cohorts with variable disease severity, Experience of Pathology, Duration of sample 
retrieval to Sample Analysis & Differences in diagnostic criteria. 
In my study, there was only one positive cytology patient out of 12 patients (D-Lap negative) 
examined. Positive cytology rate being 8.33% 
Hence institutional based study should be done to establish the significance of Peritoneal Wash 
cytology in CA Stomach. 
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PATIENT INFORMATION MODULE 
You are being invited to be a subject in this study. 
Before you participate in this study, I am giving you the following details about this trial, 
which includes the aims, methodology, intervention, possible side effects, if any and outcomes: 
All Patients with proven adenocarcinoma of the stomach after diagnostic work-up will be 
included in this study. A detailed clinical history will be taken following a standardized 
proforma. A detailed clinical examination will be made and relevant basic investigations will be 
done at the time of admission. The results arising from this study will be analyzed and used for 
academic purposes. You will be given clear instructions at every step and you are free to ask/ 
clarify any doubts. Your identity will remain confidential. You are free to withdraw from this trial 
at any point of time, without any prior notice &/ or without any medical or legal implications. 
I request you to volunteer for this study. 
Thanking You, 
 
 
Investigator’s Sign       Patient’s Sign 
(Dr.G.RANGARAJAN)      (Name:                            ) 
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INFORMED CONSENT 
Name:       Age/ Sex:  IP: 
I herewith declare that I have been explained in a language fully understood by me regarding the 
purpose of this study, methodology, proposed intervention, possible complications, if any. 
I have been given an opportunity to discuss my doubts and I have received the appropriate 
explanation. 
I understand that my participation in this study is completely voluntary and that I am free to 
withdraw from this study at anytime without any prior notice &/ or without having my medical 
or legal rights affected. 
I permit the author and the research team full access to all my records at any point, even if I have 
withdrawn from the study. However my identity will not be revealed to any third party or 
publication. 
I herewith permit the author and the research team to use the results and conclusions arising from 
this study for any academic purpose, including but not limited to dissertation/ thesis or 
publication or presentation in any level. 
Therefore, in my full conscience, I give consent to be included in the study and to undergo any 
investigation or any intervention therein. 
 
Patient’s Sign       Investigator’s Sign 
        (Dr.G.RANGARAJAN) 
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அரசு ஸ்டான்லி மருத்துவக் கல்லூரி, சென்னை - 600 001. 
பங்கு சபறுபவரின் ஒப்பம் 
ஆராய்ச்சியின் தனைப்பு  :  இரைப்ரை புற்றுந ோய் மற்றும் உள்ளுரை 
சுத்தம் உயிைணிவியல் முக்கியத்துவ ம்    
ைற்ைிய ஆய்வு 
 
ஆராய்ச்சி நனடசபறும் இடம் :  அரசு ஸ்டான்லி மருத்துவக் கல்லூரி,  
 சென்னை - 1. 
 
பங்கு சபறுபவரின் 
சபயரும் முகவரியும்  : 
 
நான், ................................................................. இந்த ஆராய்ச்சியின் 
விவரங்கனை எைது சொந்த சமாழியில் கூற அறிந்து சகாண்டடன். 
 
இந்த ஆராய்ச்சியின் முழுவிவரங்கனையும் நான் அறிந்து சகாண்டடன். இந்த 
ஆராய்ச்சியில் நான் பங்குசபறும் டபாது எைக்கு ஏற்படும் நன்னம தீனமகனை 
முழுவதுமாக அறிந்து சகாண்டடன். 
 
இந்த ஆராய்ச்சியின் டபாது எப்டபாது டவண்டுமாைாலும் நான் விைகிக்சகாள்ைைாம் 
என்பதயும், அதைால் எைக்கு கினடக்கும் மருத்துவத்தில் எந்தவித மாற்றடமா 
பாதிப்டபா இருக்காது என்றும் அறிடவன். இந்த ஆராய்ச்சியில் நான் 
பங்குசபறுவதற்காக நான் எந்தவித ென்மாைமும் (பணமாகடவா, சபாருைாகடவா) 
வாங்கமாட்டடன். இந்த ஆராய்ச்சியின் முடிவுகனை, என் அனடயாைங்கனை 
குறிப்பிடாமல் மருத்துவ இதழ்களில் சவளியிட எைக்கு எந்த ஆட்டெபனையும் 
இல்னை. இந்த ஆரய்ச்சியில் என் பங்கு என்ை என்பனத அறிடவன். இந்த 
ஆராய்ச்சிக்கு எைது முழுஒத்துனைப்னபயும் தருடவன் என்று உறுதி அளிக்கிடறன். 
 
பங்கு சபறுபவரின் சபயரும் முகவரியும்: 
 
பங்கு சபறுபவரின் னகசயாப்பம் / விரல்டரனக : 
 
டததி: 
 
ஆராய்ச்சி செய்பவரின் சபயரும் னகசயாப்பமும் : 
 
                Dr. நகோ. ைங்கைோஜன் 
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PROFORMA 
Investigator: Dr.G.RANGARAJAN, PG 2nd year – MS (General Surgery) 
Guide: Prof. Dr.LALITHKUMAR, Chief, Unit S7 
• NAME :        SL. NO: 
• AGE /SEX:        IP NO: 
• ADDRESS WITH CONTACT NUMBER: 
• DATE OF ADMISSION:      DATE OF DISCHARGE:  
 
HISTORY OF PRESENTING ILLNESS: 
  
  
PAST HISTORY:       PERSONAL HISTORY: 
    
 
GENERAL EXAMINATION:   
PR:    BP:      
LOCAL EXAMINATION OF ABDOMEN: 
 
 
SYSTEMIC EXAMINATION: 
Respiratory System: 
Cardio Vascular System:  
Central Nervous System: 
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CLINICAL DIAGNOSIS: 
INVESTIGATIONS: 
Hematological    Biochemical 
Hemoglobin:     BloodSugar: 
TLC:      SerumElectrolytes: 
DLC:      LFT: T. Bilirubin: DBR: SGOT:    SGPT:       
ALP: 
Platelet counts:    T. Protein: Serum Albumin: 
Hematocrit:                                                    RFT: 
Coagulation Profile:        Blood Group:                                 
ECG:      Chest X ray: 
USG ABDOMEN & PELVIS: 
 
 
Esophago gastro duodenoscopy: 
 
CECT Abdomen/Pelvis: 
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Diagnostic Lap and peritoneal wash cytology:     
 
FINAL DIAGNOSIS: 
 
SURGERY: PALLIATIVE OR CURATIVE  
 
 TYPE OF SURGERY: 
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